Insider Selling: ImmunityBio (NASDAQ:IBRX) Director Sells 50,000 Shares of Stock

ImmunityBio, Inc. (NASDAQ:IBRX) Director Christobel Selecky sold 50,000 shares of the business’s stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $5.00, for a total value of $250,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Christobel Selecky also recently made the following trade(s):

• On Tuesday, January 20th, Christobel Selecky sold 25,000 shares of ImmunityBio stock. The stock was sold at an average price of $7.51, for a total value of $187,750.00.

ImmunityBio Price Performance

NASDAQ IBRX traded up $0.44 during trading hours on Wednesday, hitting $6.92. The company’s stock had a trading volume of 95,661,091 shares, compared to its average volume of 33,482,678. The company has a market cap of $6.82 billion, a P/E ratio of -16.88 and a beta of 0.03. The company’s 50 day simple moving average is $2.54 and its two-hundred day simple moving average is $2.52. ImmunityBio, Inc. has a 12 month low of $1.83 and a 12 month high of $7.98.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. The business had revenue of $32.06 million during the quarter, compared to analysts’ expectations of $31.88 million. As a group, research analysts predict that ImmunityBio, Inc. will post -0.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on IBRX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. D. Boral Capital restated a “buy” rating and issued a $24.00 price target on shares of ImmunityBio in a research report on Tuesday. Piper Sandler boosted their price objective on shares of ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, Jefferies Financial Group increased their target price on shares of ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

Key Headlines Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: FDA discussions gave ImmunityBio a clear path to resubmit an sBLA for ANKTIVA in papillary non‑muscle invasive bladder cancer, and the company plans to submit additional information within 30 days — a direct catalyst for upside. ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission
• Positive Sentiment: Company press release confirmed a Type B End‑of‑Phase meeting with the FDA and outlined next steps for ANKTIVA’s sBLA, reinforcing the regulatory-path narrative that investors are rewarding. ImmunityBio Advances Regulatory Discussions with FDA
• Positive Sentiment: HC Wainwright raised its long‑term outlook (FY2030 EPS estimate to $0.68), signaling growing analyst optimism about ImmunityBio’s future earnings power (consensus had been negative).
• Positive Sentiment: At least one independent shop reaffirmed a “buy” and a high price target ($24), which may support further speculative buying interest. Benzinga
• Neutral Sentiment: The stock’s rally has extended over multiple sessions (reported as a 12‑day run in some outlets), driven in part by momentum trading and heavy volume rather than fresh clinical data. ImmunityBio (IBRX) rockets on 12th day, hits fresh high
• Neutral Sentiment: Market coverage notes short‑sellers are under pressure as the rapid share surge forces potential covering — a technical factor that can amplify volatility but isn’t a fundamental guarantee of sustained gains. Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses
• Neutral Sentiment: Multiple outlets covered the FDA meeting and ensuing price moves; much of the market reaction reflects expectations about the timing and sufficiency of the planned resubmission analyses. ImmunityBio stock soars after FDA meeting on bladder cancer treatment
• Negative Sentiment: Some analysts and commentary warn of momentum risks — advising traders to be cautious or to trim exposure amid a speculative rally and the possibility that regulatory requests could require more data or time than investors expect. Top 3 Health Care Stocks You May Want To Dump In January

Hedge Funds Weigh In On ImmunityBio

Several large investors have recently added to or reduced their stakes in IBRX. Slow Capital Inc. acquired a new stake in shares of ImmunityBio during the 3rd quarter valued at about $25,000. Truist Financial Corp bought a new position in shares of ImmunityBio during the 3rd quarter valued at about $27,000. Swiss Life Asset Management Ltd acquired a new stake in ImmunityBio in the 3rd quarter valued at approximately $27,000. Diversify Advisory Services LLC acquired a new position in ImmunityBio during the second quarter valued at approximately $27,000. Finally, Summit X LLC acquired a new position in ImmunityBio during the second quarter worth approximately $28,000. 8.58% of the stock is currently owned by institutional investors.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.